Previous 10 | Next 10 |
Independent Advisory Firm ISS Recommends Seneca Biopharma, Inc. Stockholders Vote for Proposed Merger and Reverse Stock Split PR Newswire GERMANTOWN, Md. , March 17, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading ind...
Are These Biotech Penny Stocks To ‘Buy’ Or Are They On The ‘Sell’ List? In the last year, many have taken an interest in biotech penny stocks. A significant driving factor of this was that many of these corporations shifted focus to creating a vaccine for the...
CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) to form Palisade Bio, Inc., today announced that t...
4 Penny Stocks To Watch For February 2021 I’m not going to lie; we talk about penny stocks a lot. If you’re among the new batch of traders, you must’ve heard about these cheap shares but might not know what you’re looking at. In this article, I’m g...
Cheap Penny Stocks To Watch Right Now; Are They On Your List To Buy? Penny stocks on Robinhood have gotten a jolt of momentum this month. Thanks, in part, to outlets like Reddit, cheap stocks are coming into the mainstream. More importantly, “the retail investor” is ge...
Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements PR Newswire GERMANTOWN, Md. , Jan. 25, 2021 /PRNewswire/ -- Seneca Biopharma, Inc, (NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unm...
Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. TenNor Therapeutics (Suzhou), a company that develops dual-action antibiotics, announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation ...
Seneca Biopharma (SNCA) posts disappointing preliminary, top-line results from its placebo controlled Phase 2 stroke study testing its human neural stem cell therapy, NSI-566, in patients with stable deficits in motor function due to ischemic stroke.The study enrolled 23 patients who were ran...
Seneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic Stroke PR Newswire GERMANTOWN, Md. , Jan. 20, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on deve...
Leading BioSciences ((LBS)), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma ([[SNCA]] +7.2%), announces that the FDA has granted Fast Track designation to LB1148 for the treatment of postoperative gastrointestinal ((GI)) d...
News, Short Squeeze, Breakout and More Instantly...
Neuralstem Inc. Company Name:
SNCA Stock Symbol:
NYSE Market:
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc. - Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021 - New combined company, Palisades Bio, expected to begin trading on Nasdaq Capital...